Fibroblast Growth Factor 23 and Sclerostin in Relation to Calcium in COVID-19 Patients

Serum Levels of Fibroblast Growth Factor 23 and Sclerostin in Relation to Serum Calcium Level in COVID 19 Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05275491

Enrollment

Registered

2022-03-11

Start date

2022-05-01

Completion date

2023-02-01

Last updated

2023-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

COVID-19, Hypocalcemia, Fibroblast growth factor 23 (FGF23), Sclerostin

Brief summary

Hypocalcemia is associated with COVID-19 patients and is linked to poor prognosis, Fibroblast growth factor 23 (FGF23) and Sclerostin inhibit vitamin D activation and are linked to hypocalcemia. Levels of FGF23 and Sclerostin in COVID-19 patients will be detected and correlated to calcium levels.

Detailed description

COVID 19 is a current worldwide pandemic caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2. Hypovitaminosis D and hypocalcaemia have been reported to be associated with COVID 19 infection, they are considered good biomarkers of clinical severity of COVID 19. Poor prognosis related to hypocalcemia is increased in elderly patients. Fibroblast growth factor 23 and sclerostin are secreted from the bone, they decrease active vitamin D levels. Their levels and their relation to calcium levels in COVID-19 patients will be detected.

Interventions

DIAGNOSTIC_TESTCalcium

Free calcium serum levels

DIAGNOSTIC_TESTFibroblast growth factor 23

Serum level

DIAGNOSTIC_TESTSclerostin

Serum level

DIAGNOSTIC_TESTparathyroid hormone

serum level

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Positive COVID 19 (Mild to moderate - severe to critical).

Exclusion criteria

* known diagnosis of CKD. * Known parathyroid disease. * Use of phosphate binder therapy within the past 3 months. * Use of calcium therapy within the past 3 months * Treatment with 25(OH) vitamin D or 1,25 (OH)(2) D * Underlying metabolic bone disease. * Underlying renal phosphate wasting disorder.

Design outcomes

Primary

Measure	Time frame	Description
Changes in serum calcium levels	6 months	Expected lower serum calcium levels in COVID 19 patients compared to control
changes in FGF23 levels	6 months	Expected higher FGF23 levels in COVID 19 patients compared to control
changes in sclerostin levels	6 months	Expected higher sclerostin levels in COVID 19 patients compared to control
Changes in parathyroid hormone levels	6 months	Expected lower levels in COVID 19 patients compared to control

Secondary

Measure	Time frame	Description
Relation between FGF 23 and calcium levels	6 months	A negative relation is expected
Relation between sclerostin and calcium levels	6 months	A negative relation is expected

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026